









Markets
/
Stocks
/
nasdaq-stim
/

Neuronetics Inc

STIM

1.560USD

+0.140+9.86%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

106.77MMarket Cap

LossP/E TTM



Neuronetics Inc

1.560

+0.140+9.86%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Neuronetics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Neuronetics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 89 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Neuronetics Inc's Score

Industry at a Glance

Industry Ranking

89 / 205

Overall Ranking

239 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Neuronetics Inc Highlights

StrengthsRisks

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.

Growing

The company is in a growing phase, with the latest annual income totaling USD 74.89M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 74.89M.

Fairly Valued

The company’s latest PE is -1.88, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 42.40M shares, decreasing 26.69% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 13.74K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.95.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

6.500

Target Price

+357.75%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Neuronetics Inc is 6.97, ranking 115 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 37.30M, representing a year-over-year increase of 101.28%, while its net profit experienced a year-over-year increase of 32.20%.

Score

Industry at a Glance

Previous score

6.97

Change



Financials

5.97

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.60

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.79

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.34

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.15

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Neuronetics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Neuronetics Inc is 7.47, ranking 82 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -1.88, which is -73.42% below the recent high of -0.50 and -170.69% above the recent low of -5.09.

Score

Industry at a Glance

Previous score

7.47

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 89/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Neuronetics Inc is 8.00, ranking 60 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 7.00, with a high of 7.00 and a low of 5.50.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

6.500

Target Price

+357.75%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Neuronetics Inc

STIM

Intuitive Surgical Inc

ISRG

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Neuronetics Inc is 6.80, ranking 84 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 2.13 and the support level at 1.18, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.54

Change

0.26

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.164

Neutral

RSI(14)

40.828

Neutral

STOCH(KDJ)(9,3,3)

18.677

Neutral

ATR(14)

0.218

Low Volatility

CCI(14)

-133.635

Sell

Williams %R

78.947

Sell

TRIX(12,20)

0.543

Sell

StochRSI(14)

31.779

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.668

Sell

MA10

1.920

Sell

MA20

1.939

Sell

MA50

1.656

Sell

MA100

2.115

Sell

MA200

2.983

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Neuronetics Inc is 5.00, ranking 113 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 61.91%, representing a quarter-over-quarter increase of 7.47%. The largest institutional shareholder is The Vanguard, holding a total of 2.58M shares, representing 3.77% of shares outstanding, with 7.62% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Madryn Asset Management, LP

20.74M

-14.44%

Chernett (Jorey)

4.40M

UBS Financial Services, Inc.

2.16M

+580.70%

The Vanguard Group, Inc.

Star Investors

2.83M

+3.26%

BlackRock Institutional Trust Company, N.A.

2.12M

+3.68%

Cucuz (Sasha)

2.03M

+0.32%

Balyasny Asset Management LP

1.82M

+20.71%

Sullivan (Keith J)

1.61M

Wexford Capital LP

1.18M

+83.06%

Masters Capital Management, L.L.C.

1.00M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Neuronetics Inc is 2.08, ranking 164 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.86. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.